Cevian Capital Lifts Smith & Nephew Stake to 12.24% Without Triggering New Threshold
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Smith & Nephew Snats ( (SNN) ) just unveiled an update.
On June 17, 2026, Smith & Nephew disclosed that activist investor Cevian Capital II G.P. Limited slightly increased its stake in the company, according to a major holdings notification filed with U.S. regulators. As of June 12, 2026, Cevian’s aggregate holding rose from 12.07% to 12.24% of Smith & Nephew’s voting rights, equivalent to 103,717,469 shares held via nominee Aurora Nominees on behalf of UBS as custodian.
The increase came through modest additions in Cevian Capital II Master Fund L.P. and Cevian Capital II Co-Investment – Series P L.P., lifting their respective positions to 11.05% and 1.19% without triggering a new regulatory threshold. While the move is described as a transparency-related notification, it underlines Cevian’s continued role as a significant shareholder, reinforcing its capacity to influence governance and strategic decisions at the medtech group.
The most recent analyst rating on (SNN) stock is a Hold
with a $30.00 price target.
To see the full list of analyst forecasts on Smith & Nephew Snats stock,
see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock,
click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a UK-based medical technology company listed in London and the U.S., known for orthopaedics, sports medicine, and advanced wound management products. It serves hospitals and healthcare systems globally, competing in a consolidating medtech sector where long-term institutional shareholders can exert meaningful influence over strategy and capital allocation.
Average Trading Volume: 1,098,666
Technical Sentiment Signal: Buy
Current Market Cap: $12.87B
Find detailed analytics on SNN stock on TipRanks’ Stock Analysis page.
